Critical considerations for targeting colorectal liver metastases with nanotechnology.
colorectal cancer
drug delivery
liver metastases
nanomedicines
tumor biology
Journal
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
ISSN: 1939-0041
Titre abrégé: Wiley Interdiscip Rev Nanomed Nanobiotechnol
Pays: United States
ID NLM: 101508311
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
17
06
2019
revised:
16
08
2019
accepted:
16
08
2019
pubmed:
1
10
2019
medline:
16
2
2021
entrez:
1
10
2019
Statut:
ppublish
Résumé
Colorectal cancer remains a significant cause of morbidity and mortality worldwide. Half of all patients develop liver metastases, presenting unique challenges for their treatment. The shortcomings of conventional chemotherapy has encouraged the use of nanomedicines; the application of nanotechnology in the diagnosis and treatment of disease. In spite of technological improvements in nanotechnology, the complexity of biological systems hinders the prospect of nanomedicines being applied in cancer therapy at the present time. This review highlights current biological barriers and discusses aspects of tumor biology together with the physicochemical features of the nanocarrier, that need to be considered in order to develop effective nanotherapeutics for colorectal cancer patients with liver metastases. It becomes clear that incorporating an interdisciplinary approach when developing nanomedicines should assure appropriate disease-driven design and that this will form a critical step in improving their clinical translation. This article is characterized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
Identifiants
pubmed: 31566913
doi: 10.1002/wnan.1588
pmc: PMC7027529
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1588Subventions
Organisme : Medical Research Council
ID : MR/L006758/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C55939/A22570
Pays : United Kingdom
Informations de copyright
© 2019 The Authors. WIREs Nanomedicine and Nanobiotechnology published by Wiley Periodicals, Inc.
Références
Mol Cancer Res. 2006 May;4(5):293-302
pubmed: 16687484
J Control Release. 2000 Mar 1;65(1-2):271-84
pubmed: 10699287
Bioconjug Chem. 2016 Aug 17;27(8):1830-8
pubmed: 27391789
ACS Nano. 2018 Oct 23;12(10):10130-10141
pubmed: 30117736
Eur Rev Med Pharmacol Sci. 2012 Jun;16(6):737-42
pubmed: 22913203
ACS Nano. 2018 Mar 27;12(3):2138-2150
pubmed: 29320626
Clin Pharmacokinet. 2003;42(5):419-36
pubmed: 12739982
Biomaterials. 2012 May;33(15):3909-18
pubmed: 22374455
Signal Transduct Target Ther. 2018 Mar 16;3:7
pubmed: 29560283
Toxicol Sci. 2013 Feb;131(2):537-47
pubmed: 23086748
ACS Nano. 2012 May 22;6(5):4122-31
pubmed: 22486639
Hum Vaccin Immunother. 2014;10(11):3224-35
pubmed: 25483675
Stem Cell Res. 2018 Mar;27:109-120
pubmed: 29414601
Anal Chem. 2016 Nov 1;88(21):10661-10666
pubmed: 27726379
Front Pharmacol. 2018 Jan 23;9:6
pubmed: 29410625
Biomaterials. 2011 May;32(13):3435-46
pubmed: 21295849
Cancer Res. 2013 Apr 15;73(8):2412-7
pubmed: 23423979
Cancer Treat Rev. 2015 Nov;41(9):729-41
pubmed: 26417845
J Control Release. 2011 Aug 10;153(3):198-205
pubmed: 21663778
Nat Immunol. 2013 Oct;14(10):986-95
pubmed: 24048120
Bioeng Transl Med. 2016 Jun 03;1(1):10-29
pubmed: 29313004
BMC Cancer. 2018 Jan 15;18(1):78
pubmed: 29334918
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Rev Clin Oncol. 2015 Oct;12(10):607-19
pubmed: 26215044
J Control Release. 2013 Apr 28;167(2):130-7
pubmed: 23391444
Mol Pharm. 2008 Jul-Aug;5(4):505-15
pubmed: 18672949
Sci Rep. 2016 Sep 22;6:33808
pubmed: 27654170
J Surg Res. 1997 Feb 1;67(2):179-85
pubmed: 9073565
PLoS Genet. 2016 Jul 29;12(7):e1006225
pubmed: 27472274
J Drug Target. 2008 Feb;16(2):108-23
pubmed: 18274932
Front Oncol. 2018 Nov 26;8:544
pubmed: 30534533
Nat Rev Clin Oncol. 2019 Aug;16(8):469-493
pubmed: 30816337
Br J Cancer. 2017 Nov 7;117(10):1427-1441
pubmed: 28982110
Nanomedicine. 2016 Jul;12(5):1365-74
pubmed: 26961463
Cancer. 2013 Dec 15;119(24):4223-30
pubmed: 24105075
Int J Nanomedicine. 2014 May 06;9 Suppl 1:51-63
pubmed: 24872703
Acc Chem Res. 2011 Oct 18;44(10):1018-28
pubmed: 21851104
Lancet Oncol. 2018 Feb;19(2):e81
pubmed: 29276021
J Biol Chem. 2019 Jan 4;294(1):281-289
pubmed: 30409905
Biomaterials. 2014 Feb;35(5):1735-43
pubmed: 24290696
Cancer. 2006 Apr 1;106(7):1624-33
pubmed: 16518827
Physiol Rev. 2011 Jul;91(3):1071-121
pubmed: 21742796
Pharmaceuticals (Basel). 2018 Apr 09;11(2):
pubmed: 29642542
Br J Surg. 1989 Jun;76(6):545-8
pubmed: 2474356
Int J Pharm. 2009 Dec 1;382(1-2):222-33
pubmed: 19664697
J Control Release. 2015 Mar 10;201:78-89
pubmed: 25526702
Cancer Chemother Pharmacol. 2014 Dec;74(6):1125-37
pubmed: 25228368
Trends Cancer. 2018 Apr;4(4):292-319
pubmed: 29606314
Regul Toxicol Pharmacol. 2019 Aug;106:187-196
pubmed: 31051191
Nanomedicine (Lond). 2016 Sep;11(18):2443-56
pubmed: 27529192
Colloids Surf B Biointerfaces. 2017 Oct 1;158:356-362
pubmed: 28719856
Hepat Oncol. 2016 Aug;3(3):193-200
pubmed: 30191041
Clin Exp Metastasis. 2019 Feb;36(1):57-66
pubmed: 30680598
Am J Pathol. 1993 Sep;143(3):926-36
pubmed: 7689793
Int J Nanomedicine. 2017 Apr 18;12:3137-3151
pubmed: 28458536
Lab Invest. 2010 Jan;90(1):61-7
pubmed: 19823171
Clin Cancer Res. 2012 Feb 1;18(3):688-99
pubmed: 22173549
Biomacromolecules. 2008 Feb;9(2):435-43
pubmed: 18189360
Nat Commun. 2018 Apr 12;9(1):1410
pubmed: 29650952
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
Clin Cancer Res. 2016 Dec 15;22(24):5971-5982
pubmed: 27797969
Exp Mol Pathol. 2009 Jun;86(3):215-23
pubmed: 19186176
Clin Cancer Res. 2017 Nov 1;23(21):6390-6399
pubmed: 28615370
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Mar;12(2):e1588
pubmed: 31566913
Mol Clin Oncol. 2017 Jul;7(1):113-120
pubmed: 28685087
Semin Liver Dis. 1993 Feb;13(1):39-49
pubmed: 8446907
Br J Cancer. 2004 Apr 5;90(7):1429-36
pubmed: 15054467
Nat Med. 2016 Nov 8;22(11):1209-1210
pubmed: 27824818
Adv Drug Deliv Rev. 2017 Jan 1;108:25-38
pubmed: 27137110
Cancer Res. 2006 Oct 15;66(20):10048-56
pubmed: 17047068
Front Oncol. 2018 Sep 25;8:404
pubmed: 30319969
Oncotarget. 2016 Nov 22;7(47):77183-77195
pubmed: 27791203
Adv Drug Deliv Rev. 2018 May;130:17-38
pubmed: 30009886
Toxicol Appl Pharmacol. 2016 May 15;299:78-89
pubmed: 26739622
Compr Physiol. 2015 Sep 20;5(4):1751-74
pubmed: 26426467
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
J Control Release. 2014 Sep 28;190:485-99
pubmed: 24984011
Cancer Res. 1992 Nov 15;52(22):6371-4
pubmed: 1423283
Anticancer Res. 2011 Jan;31(1):153-9
pubmed: 21273593
Cancer. 2000 Jul 15;89(2):285-7
pubmed: 10918157
J Control Release. 2011 May 10;151(3):220-8
pubmed: 21078351
World J Gastroenterol. 2014 Apr 14;20(14):3719-37
pubmed: 24744570
Clin Cancer Res. 2010 Oct 1;16(19):4822-31
pubmed: 20807756
Cell Death Dis. 2015 Feb 05;6:e1629
pubmed: 25654762
Ann Surg Oncol. 2012 Jul;19(7):2186-94
pubmed: 22395983
Nat Mater. 2016 Nov;15(11):1212-1221
pubmed: 27525571
Nanoscale. 2015 Nov 14;7(42):17745-55
pubmed: 26455329
Ther Deliv. 2011 Aug;2(8):1001-14
pubmed: 22506095
Eur J Radiol. 2011 Dec;80(3):e278-83
pubmed: 21251785
ACS Nano. 2015 Sep 22;9(9):8689-96
pubmed: 26212564
Hepatology. 2011 Aug;54(2):707-13
pubmed: 21520207
Int J Nanomedicine. 2017 Oct 31;12:7993-8007
pubmed: 29184400
Int J Cancer. 2005 Jul 20;115(6):893-902
pubmed: 15729725
ACS Appl Mater Interfaces. 2017 Sep 6;9(35):29457-29468
pubmed: 28799743
Cancer Res. 2013 Apr 1;73(7):2031-43
pubmed: 23536564
Cancer Res. 2016 Jan 15;76(2):429-39
pubmed: 26744528
Clin Cancer Res. 2009 Jan 15;15(2):692-700
pubmed: 19147776
Int J Cancer. 2018 Aug 1;143(3):709-719
pubmed: 29492958
SLAS Technol. 2017 Jun;22(3):245-253
pubmed: 28277923
Clin Transl Med. 2017 Dec 11;6(1):44
pubmed: 29230567
Chin J Cancer. 2016 Feb 12;35:19
pubmed: 26873579
J Immunol Res. 2014;2014:686879
pubmed: 24741617
ACS Nano. 2017 Mar 28;11(3):2428-2443
pubmed: 28040885
Mol Ther. 2014 Dec;22(12):2083-2092
pubmed: 25200008
J Allergy Clin Immunol. 2016 Dec;138(6):1712-1715
pubmed: 27522158
Biochem J. 2004 Jan 1;377(Pt 1):159-69
pubmed: 14505488
Theranostics. 2013 Dec 11;4(1):81-9
pubmed: 24396516
J Control Release. 2015 Apr 10;203:126-39
pubmed: 25701309
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):473-82
pubmed: 16242253
J Surg Oncol. 2008 Sep 15;98(4):247-52
pubmed: 18726886
Nat Med. 2016 Nov;22(11):1294-1302
pubmed: 27748747
Clin Exp Metastasis. 2012 Aug;29(6):541-9
pubmed: 22476470
AAPS PharmSciTech. 2014 Apr;15(2):388-99
pubmed: 24431104
Sci Transl Med. 2016 Feb 10;8(325):325ra17
pubmed: 26865565
J Oncol. 2019 Feb 25;2019:6280347
pubmed: 30930945
BMJ Open Gastroenterol. 2018 Jul 27;5(1):e000217
pubmed: 30073092
ACS Appl Mater Interfaces. 2018 Apr 4;10(13):10752-10760
pubmed: 29470042
J Control Release. 2012 Jun 10;160(2):117-34
pubmed: 22484195
J Pathol Clin Res. 2018 Jul;4(3):184-192
pubmed: 29654716
J Control Release. 2016 Oct 28;240:332-348
pubmed: 26774224
Nat Rev Dis Primers. 2015 Nov 05;1:15065
pubmed: 27189416
Mol Ther. 2011 Jan;19(1):83-92
pubmed: 20959811
Front Biosci (Landmark Ed). 2013 Jun 01;18:1435-43
pubmed: 23747894
Breast Cancer Res Treat. 2008 Mar;108(2):241-50
pubmed: 17476588
Circ Res. 2007 Feb 2;100(2):174-90
pubmed: 17272819
J Am Chem Soc. 2012 Feb 1;134(4):2139-47
pubmed: 22191645
Nanomedicine. 2012 Feb;8(2):147-66
pubmed: 21703993
Clin Cancer Res. 2008 Mar 15;14(6):1888-96
pubmed: 18347192
Cancer Res. 2007 Mar 15;67(6):2729-35
pubmed: 17363594
Sci Rep. 2015 May 27;5:10525
pubmed: 26013284
Cell Rep. 2017 Jan 3;18(1):263-274
pubmed: 28052255
Biomaterials. 2007 Feb;28(5):869-76
pubmed: 17055572
Hepatology. 2006 Sep;44(3):623-32
pubmed: 16941711
Nanoscale. 2015 Jun 28;7(24):10790-800
pubmed: 26038337
Clin Transl Med. 2019 Jul 1;8(1):21
pubmed: 31263976
Nat Rev Clin Oncol. 2010 Nov;7(11):653-64
pubmed: 20838415
Radiology. 2007 May;243(2):386-95
pubmed: 17356176
Int J Cancer. 2009 Apr 15;124(8):1860-70
pubmed: 19123477
Lancet Oncol. 2018 Aug;19(8):1027-1039
pubmed: 30001990
Curr Colorectal Cancer Rep. 2015 Jun 1;11(3):125-140
pubmed: 26441489
Nat Rev Urol. 2013 May;10(5):300-4
pubmed: 23459032
Int J Cancer. 2008 May 1;122(9):2148-53
pubmed: 18196580
Angew Chem Int Ed Engl. 2018 Feb 19;57(8):2032-2034
pubmed: 29341367
PLoS One. 2015 Oct 02;10(10):e0139752
pubmed: 26431204
Nanomedicine (Lond). 2017 Mar;12(5):491-510
pubmed: 28181470
Cancer Treat Rev. 2013 Jun;39(4):321-7
pubmed: 23244778
Immunol Res. 2009;43(1-3):210-22
pubmed: 18979076
Nanotoxicology. 2017 Mar;11(2):147-149
pubmed: 28055261
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 May;11(3):e1546
pubmed: 30556649
Cancer Chemother Pharmacol. 1998;41(2):147-54
pubmed: 9443628
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int Arch Allergy Appl Immunol. 1984;74(1):36-9
pubmed: 6706424
Cell Stem Cell. 2016 Jun 2;18(6):827-838
pubmed: 27212702
Part Fibre Toxicol. 2007 Oct 19;4:10
pubmed: 17949501
Am J Pathol. 2007 Jan;170(1):1-15
pubmed: 17200177
Transl Oncol. 2019 Jan;12(1):180-189
pubmed: 30554606
Molecules. 2018 Jul 12;23(7):
pubmed: 30002298
Ann Surg Treat Res. 2017 Oct;93(4):173-180
pubmed: 29094026
J Control Release. 2016 Nov 10;241:68-80
pubmed: 27641831
Cancers (Basel). 2018 Dec 28;11(1):
pubmed: 30597841
J Control Release. 2011 Jul 15;153(1):49-55
pubmed: 21406204
Angew Chem Int Ed Engl. 2010 Aug 23;49(36):6288-308
pubmed: 20648499
Cell. 2006 Nov 17;127(4):679-95
pubmed: 17110329
Cancer Lett. 2017 Feb 28;387:114-120
pubmed: 26850374
J Nanobiotechnology. 2012 Aug 14;10:36
pubmed: 22891637
Adv Drug Deliv Rev. 2014 Feb;66:2-25
pubmed: 24270007
Transl Oncol. 2019 Sep;12(9):1196-1205
pubmed: 31228770